Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Long who wrote (1223)	12/13/1997 11:20:00 PM
From: Marshall Teitelbaum	Respond to of 2205

Bruce, What would happen with ORG depends on many factors: when/if they get on a panel, when they will run out of $ if not, or when will they get taken over(such as by Novartis, the popular rumor for some time). My guess is that without good progress and good chance for fda approval for apligraf, we could count novartis out, but who knows? Without an fda panel meeting for them soon, they are starting to run low on money without some help. The up side appears much less than the down side right now, but figuring exactly when to cover is always a tricky subject for short sellers. Of course, running out of money would tell you exactly where there share price would go, but can never count on any particular thing to happen. Good luck. It looks like all biotechs' share prices, for the most part, are being held back right now, as are techs in general. In this kind of manic-depressive market many are inclined to go over to the safer large caps/blue chips and let these fellas rot. However, if you happen to pick the right companies, the values are fairly reasonable now. There was an article on the 11th about the biotech investor conference which took place on the 13th, with the usual pair of Murphy and McCamant presenting, along with Micheal Adams from Dain Bosworth. Generally it had Adams' past pick of Amgen after his wife had gotten cancer and how investors who weathered the 50% drop along the way ended up getting 25X their money in 10 years. He had his 2 recommendations of ICOS and ALCD, along with his picks of 3 good companies which he felt were currently undervalued...GENZ, ATIS, and LIPO. Interesting. I still think that with the onset of january, if the market settles down a bit, and the approaching meeting, ATIS should begin to pick up, although it could possibly get a boost after the options expiration this week too theoretically. Either way, the key is that the company looks solid, and all usually works out when that is the case....that is, with a solid product(fda tells us how solid companies actually are!). Take care, Marshall